Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, r
2 hours ago
- #Clinical Trial
- #Mantle Cell Lymphoma
- #Ibrutinib
- The TRIANGLE trial evaluated adding autologous stem-cell transplantation (ASCT) to an ibrutinib-containing first-line regimen in younger (18-65 years) mantle cell lymphoma patients.
- After 54.9 months median follow-up, group A+I (ibrutinib plus ASCT) did not show superiority in failure-free survival over group I (ibrutinib alone; 82% vs 81% at 4 years, HR 0.86).
- Both ibrutinib-containing groups improved overall survival compared to group A (standard ASCT), but ASCT addition increased toxicity without supplementary benefit.